Who is eligible for clinical trial NCT06314282?

Participants must meet protocol criteria for Systemic Lupus Erythematosus (SLE). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06314282 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-16

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use (NCT06314282)

INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.

Who can join: Review the eligibility criteria below.

Location: Research Site — Buenos Aires

Age range: 18 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

Research Site — Buenos Aires,
Research Site — Córdoba,
Research Site — Guangzhou,
Research Site — Hong Kong,
Research Site — Shenzhen,
Research Site — Zhongshan,
Research Site — Zhuhai,
Research Site — San José,
Research Site — Alexandria,
Research Site — Cairo,
Research Site — Guatemala City,
Research Site — Aktobe,
Research Site — Almaty,
Research Site — Almaty,
Research Site — Astana,
Research Site — Astana,
Research Site — Pavlodar,
Research Site — Semey,
Research Site — Shymkent,
Research Site — Kuwait City,
Research Site — Mexico City,
Research Site — Mérida,
Research Site — Muscat,
Research Site — Doha,
Research Site — ASIR,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Systemic Lupus Erythematosus (SLE)

Descartes-08 for Patients With Systemic Lupus Erythematosus — Oceanside, California
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Los Angeles, California
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Farmington, Connecticut
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — Bethesda, Maryland
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants — Mesa, Arizona
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires — Bethesda, Maryland

Explore by condition: All Systemic Lupus Erythematosus (SLE) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗